Enveda Raises $130M in Series C Funding to Advance AI-Powered Drug Discovery
Enveda is revolutionizing drug discovery by leveraging AI to harness nature's chemical biodiversity.
Company Name: Enveda
Location: Boulder, CO
Sector: Biotechnology
Funding Details:
Enveda, a biotechnology company translating nature into new medicines using AI, raised $130M in Series C funding. The round was led by Kinnevik and FPV, with participation from new and existing investors including Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, Cresset Partners, The Nature Conservancy, and Henry R. Kravis.
Purpose of Funding:
The funds will enable Enveda to:
- Deliver clinical catalysts across multiple programs in 2025 and 2026.
- Advance its pipeline of 10 development candidates and numerous discovery programs.
- Invest in its proprietary AI-powered platform.
Leadership:
- Founder and CEO: Viswa Colluru
About Enveda:
Enveda is revolutionizing drug discovery by leveraging AI to harness nature's chemical biodiversity. The company uses cutting-edge tools to identify, characterize, and organize molecules produced by living organisms, building a comprehensive database of chemical solutions to tackle pressing medical challenges.
In October, Enveda achieved a major milestone with IND clearance from the U.S. Food and Drug Administration for ENV-294, a novel oral anti-inflammatory agent targeting atopic dermatitis and other inflammatory conditions. ENV-294 entered Phase I clinical trials at the end of October, marking the first candidate discovered using the Enveda platform.
